Jason A. Keyes, Chief Financial Officer at BlossomHill Therapeutics, Inc. (BLSM), bought 700 shares at $16.00 ($11K) on 2026-08-10, disclosed to the SEC on 2026-08-10.
BlossomHill Therapeutics CFO Jason A. Keyes purchased $11,200 of stock at $16.00, marking the largest insider purchase in the company's history and signaling strong conviction in the biotech's near-term prospects.
The stock is currently trading at $16.02, just 2.76% below its 52-week high of $16.475, indicating the shares are trading near the top of their recent range despite the insider buying.
Insider cluster momentum: Two other insiders purchased shares in the last 30 days, creating a buying cluster that may drive further momentum.
Insufficient data — needs manual review
Something here stands out, but not much.
| Filing → |
| EQ | SELL | 2024-09-27 | $8K | — | Filing → |
| EQ | SELL | 2024-07-18 | $9K | — | Filing → |
| EQ | SELL | 2022-08-30 | $20K | — | Filing → |